SARASOTA, Fla., March 6 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation (“IBC” or the “Company”) announces the appointment and engagement of The Kappa Group East and Harvey Hendler to the Strategic Advisory Board of the company.
As one of the nation’s premier management consulting firms, KappaEast, led by Harvey Hendler, specializes in strategic business planning and sales performance/operations. KappaEast is a leader in helping clients around the globe devise and execute effective strategies to improve their operation and achieve mission success, and will be working closely with the senior leadership team of IBTY. Mr. Hendler has broad and extensive business experience and the firm’s approach has been applied in hundreds of engagements with companies ranging in size from start-up pre-IPOs to the Fortune 100s.
Mr. Hendler has applied his expertise in the hardware, software, networking, telecommunications industries, as well as financial, professional services and venture funding. Some of Kappa’s pharma/chemical clients include Dow, FMC, Pfizer, GlaxoSmithKline, Millennium and BASF. ( http://www.kappaeast.com )
Harvey Hendler states: “We are exited to be working with the IBTY team in the development of their go-to-market strategy and the tactical execution plan to enable them to rapidly scale to become the global leader in the next wave of biotechnology.”
“KappaEast and Harvey Hendler will provide IBC the tools and strategy necessary for commercial success of our technology. We are well positioned to develop, manufacture and roll out 100-plus biologically produced chemicals over the next few years. Harvey’s expertise will enhance our ability to execute efficiently and effectively our sales engine strategy via leveraging the existing distribution infrastructure already in place in the chemical Industry,” states Ron Doran, president and director of IBC.
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high value chemicals at significantly lower costs, with a substantially lower environmental impact than traditional methods, and with a higher purity. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC will bring to market new and established chemicals that are in high demand for use in Flavors and Fragrances, Fine chemicals, Pharmaceutical, Agricultural, Environmental and Bio-Energy applications. IBC’s pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes, and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of “designer” enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled-up to large, commercial production levels. IBC’s core intellectual property utilizes patented technologies exclusively licensed from Oxford University and Rice University. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and will seek to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable biological-based solutions and related intellectual property patents. For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements.” These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Industrial Biotechnology Corp. “expects,” “should,” “believes,” “anticipates” or words of similar import. Similarly, statements that describe Industrial Biotechnology Corp.'s future plans, objectives or goals are also forward- looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corp., as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corp. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corp. does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Industrial Biotechnology Corporation
CONTACT: David West, Industrial Biotechnology Corporation, +1-941-925-2500